StockNews.com Begins Coverage on Aethlon Medical (NASDAQ:AEMD)

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Wednesday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research note on Monday.

Aethlon Medical Trading Down 7.8 %

NASDAQ AEMD opened at $0.42 on Wednesday. The company has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $0.50. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $1.85. The company has a market cap of $6.00 million, a P/E ratio of -0.26 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. Sell-side analysts predict that Aethlon Medical will post -0.73 EPS for the current year.

Institutional Investors Weigh In On Aethlon Medical

Hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC bought a new stake in shares of Aethlon Medical during the 4th quarter worth $25,000. Allegiance Financial Group Advisory Services LLC bought a new stake in shares of Aethlon Medical during the 4th quarter worth $26,000. Sassicaia Capital Advisers LLC bought a new stake in Aethlon Medical in the 4th quarter valued at about $31,000. Virtu Financial LLC bought a new stake in Aethlon Medical in the 4th quarter valued at about $81,000. Finally, Boothbay Fund Management LLC bought a new stake in Aethlon Medical in the 4th quarter valued at about $186,000. 1.99% of the stock is currently owned by institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.